BioCentury | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

...osteosarcoma and Lesch-Nyhan syndrome. St. Vincent’s Institute of Medical Research; University of Sydney Distillery Therapeutics RecQ mediated genome instability 1 (RMI1)...
BioCentury | Jun 11, 2019
Distillery Therapeutics

Inhibiting FANCM-TOP3A-RMI1 interaction for osteosarcoma, Lesch-Nyhan syndrome

...inhibitors of the FANCM-RMI1 interaction. TARGET/MARKER/PATHWAY: FA complementation group M (FANCM); topoisomerase III α (TOP3A); RecQ mediated genome instability 1 (RMI1)...
Items per page:
1 - 2 of 2